Krystal Biotech Inc (KRYS) Stock Price, Quote & News

Company Profile

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical tri...

Industry: Biotechnology

Sector: Healthcare

Phone: 412 586 5830

Website: www.krystalbio.com

Address:

2100 Wharton Street, Suite 701, Pittsburgh, United States

zampy Jun. 28 at 2:40 PM

$KRYS The os is 29m and tradable float about 25m...the shirt is 3m shares guessing in valuation which is 13% pretty high. The sympathy play $INMB has a mkt cao of 35m and a gigantic short of 3.6m shares in a tradable float of 13m shares..it will take 6.5 to 18 days to cover depending on what data you use. If Im $KRYS seems ti make sense to team up with $INMB who can systematically treat internal/external. Perfect compliment for $KRYS.

0 · Reply

zampy Jun. 28 at 1:17 PM

$KRYS $KRYS receives 750k per patient over various regions. I was mistaken yesterday about the sympathy play $INMB I stated 380k per patient it is 750k for the entire body inside and out they will charge. Hence 10% of 300 patients is 30 patients at 750k=22m .82 cents a share in earnings in the 10% they garner. So .82 centsx20 multiple ( as KRYS IS 23X) equates to $16 based on 10% of the 300 patients. My apologies....

0 · Reply

zampy Jun. 27 at 6:16 PM

$INMB continued. 5. Massive cost savings. Regulators agreed to a literature supported ficused non clinical safety package. This completely bypasses the need for redundant capital intensive animal testing. Saving major dilution and millions in cash. Regulatory uncertainty is removed on the manufacturing /CMC side. Enormous! The parh for commercialization for Cordstrom is ready to roll. $KRYS 10B CAP Treats external...$INMB 35M CAP treats systematic i side out with IV Infusion. Bottom line Blue skies ahead the stock was muted because of the reconstitution Thurs/Friday..If not for that well over $2.X plus. So if we take 10% of the 300 patients at 380k per being ultra conservative thats 11m on 27m os .41 cents a share x 20x well over $8.X taking 10% of market place. With 3.6m short because of our past failures in alzheimers NO ONE ON THE PLANET KNOWS ABOUT CORDSTROM..The fuse will be lit here asap it will get duscivered and the shorts will accelerate the price dramatically!!!

0 · Reply

zampy Jun. 27 at 3:41 PM

$INMB The king of the soace is $KRYS sitting at 1ob which is justified. I wonder do they have an interest in $INMB sitting at a tiny mkt cao 35m that treats inside out vs $KRYS externally. I believe we will hear noise about a potential deal with Babe Ruth $KRYS. It makes too much sense.

0 · Reply

zampy Jun. 27 at 3:37 PM

$KRYS The Systemic Solution. $KRYS deserves the 10b valuation it gets at 23x. $INMB ebstrocel is a IV infusion that works from the inside out. Safely traveling thru the bloodstream to treat both the external skin and internal organs. The fast track catalyst. The UK on Thursday was approved by the MHRA in less than 3 months vs the normal 20 months. Greenlighting smaller specialized data. As the patient pool is 300 in the UK. The UK has 300 cases so if $INMB captures 10% 30 patients that 380k per equates to 11m. So 27m os ÷ 11m sales is .41 cents a share at a 20x is slightly over $8.X on a tiny 35m mt cap. I wonder if KRYS has an interest in $INMB being they do it systematic? Thoughts are welcomed...$KYRS has been incredible 400m cap to 10b. This could potentially ramp up their revenues rapidly. As the sit on an enormous amount of cash

0 · Reply

zampy Jun. 27 at 3:23 PM

$KRYS The validation: $KRYS completely de-risked the Eperdermolysis bullosa market bring in an enormous 116m for Q1 and proving that each orphan patient brings in a staggering 95% gross profit margins. Simply incredible. The valuation Arb. While $KRYS commands a 10b mkt cap $ INMB sits at an anemic 36m mkt cap with 24m in cash. Creating an enormous disparity for anyone looking for a sympathy play. The Clinical Gap. Vyjuvek is a major medical breakthrough. But its topical delivery has strict surface area restrictions per session. It can not reach the devastating internal esophageal and mucocel blistering that young children suffer. Part 1

0 · Reply

Night_Owl_Biotech Jun. 27 at 2:07 PM

Commercial-stage non-oncology revenue multiples for those with 1st approvals before 12/31/2023. The $ARDX value proposition is beyond self-evident compared to the entire comm'l-stage bio peer group. We understand why Xphozah is not worth a peer multiple but why not Ibsrela? $KRYS trades @ staggering multiples. We know Vyjuvek will do $500MM in EB its sleep. We struggle with the KRYS oncology franchise (trading higher than BPMC's exit). Any input around next inflection point would be genuinely appreciated? We still like $TARS & $NBIX profile versus the others in this specific peer group. Could KRYS trade up to 4.0X 5-year sales? We do not know. $RYTM appears the 2nd outlier. Recall the last 9 commercial-stage bio exits were priced @ 0.68 to 1.02X 5-year sales projections (per the acquiree management). As always, this is not investment advice. We're usually wrong when we identify undervalued stocks.

3 · Reply

WAJeff Jun. 26 at 11:15 PM

$KRYS $376.28 ath

0 · Reply

WAJeff Jun. 25 at 2:37 PM

$KRYS $357.73 ath

0 · Reply

Cutlass Jun. 22 at 12:50 PM

$KRYS Ahh the good old days in the 30's and 40's - I sold out awhile back - 💥

1 · Reply

Krystal Biotech price target raised to $403 from $306 at TD Cowen

2026-06-16T13:08:12.000Z - 18 days ago

Krystal Biotech price target raised to $361 from $310 at H.C. Wainwright

May 21, 2026, 8:00 AM EDT - 6 weeks ago

Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

CRBP

May 20, 2026, 7:00 AM EDT - 6 weeks ago

Krystal Biotech Slides: Corporate presentation

2026-05-18T12:17:39.000Z - 6 weeks ago

Krystal Biotech announces UK MHRA approval of Vyjuvek

May 18, 2026, 8:00 AM EDT - 6 weeks ago

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

May 15, 2026, 4:00 PM EDT - 7 weeks ago

Krystal Biotech Transcript: AGM 2026

2026-05-15T18:26:55.000Z - 7 weeks ago

U.K.’s MHRA approves Krystal’s Vyjuvek for dystrophic epidermolysis bullosa

May 13, 2026, 2:20 PM EDT - 7 weeks ago

Krystal Biotech Transcript: Bank of America Global Healthcare Conference 2026

May 7, 2026, 8:00 AM EDT - 2 months ago

Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

2026-05-05T12:35:28.000Z - 2 months ago

Krystal Biotech price target raised to $300 from $295 at Evercore ISI

2026-05-05T10:40:32.000Z - 2 months ago

Krystal Biotech price target raised to $378 from $371 at Citi

2026-05-04T16:07:40.000Z - 2 months ago

Krystal Biotech price target lowered to $311 from $338 at Clear Street

May 4, 2026, 8:30 AM EDT - 2 months ago

Krystal Biotech Earnings Call Transcript: Q1 2026

May 4, 2026, 8:30 AM EDT - 2 months ago

Krystal Biotech Earnings release: Q1 2026

May 4, 2026, 8:30 AM EDT - 2 months ago

Krystal Biotech Quarterly report: Q1 2026

May 4, 2026, 8:30 AM EDT - 2 months ago

Krystal Biotech Slides: Q1 2026

2026-05-04T11:15:40.000Z - 2 months ago

Krystal Biotech sees FY26 R&D and SG&A expense $175M-$195M

2026-05-04T11:06:39.000Z - 2 months ago

Krystal Biotech reports Q1 EPS $1.83, consensus $1.42

May 4, 2026, 7:00 AM EDT - 2 months ago

Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Krystal Biotech to Present at Upcoming Scientific Conferences

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026

Apr 3, 2026, 8:00 AM EDT - 3 months ago

Krystal Biotech Proxy statement: Proxy filing

Apr 3, 2026, 8:00 AM EDT - 3 months ago

Krystal Biotech Proxy statement: Proxy filing

2026-03-26T20:23:32.000Z - 3 months ago

Krystal Biotech initiated with a Peer Perform at Wolfe Research

2026-03-24T11:35:21.000Z - 3 months ago

Krystal Biotech price target raised to $325 from $318 at BofA

Mar 4, 2026, 6:00 AM EST - 4 months ago

Krystal Biotech Slides: Corporate presentation

Mar 3, 2026, 3:10 PM EST - 4 months ago

Krystal Biotech Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-25T12:03:05.000Z - 4 months ago

Krystal Biotech price target raised to $284 from $224 at Guggenheim

2026-02-18T13:01:08.000Z - 4 months ago

Krystal Biotech price target raised to $323 from $220 at Chardan

2026-02-18T11:11:02.000Z - 4 months ago

Krystal Biotech price target raised to $371 from $336 at Citi

2026-02-17T18:35:39.000Z - 4 months ago

Krystal Biotech price target raised to $371 from $310 at Jefferies

Feb 17, 2026, 8:30 AM EST - 4 months ago

Krystal Biotech Earnings Call Transcript: Q4 2025

Feb 17, 2026, 8:30 AM EST - 4 months ago

Krystal Biotech Annual report: Q4 2025

Feb 17, 2026, 8:30 AM EST - 4 months ago

Krystal Biotech Earnings release: Q4 2025

Feb 17, 2026, 8:30 AM EST - 4 months ago

Krystal Biotech Slides: Q4 2025

2026-02-17T12:11:57.000Z - 4 months ago

Krystal Biotech sees FY26 non-GAAP R&D, SG&A expense $175M-$195M

2026-02-17T12:05:09.000Z - 4 months ago

Krystal Biotech reports Q4 EPS $1.70, consensus $1.61

Feb 17, 2026, 7:00 AM EST - 4 months ago

Krystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results

Feb 10, 2026, 8:00 AM EST - 5 months ago

Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

2026-02-09T13:11:11.000Z - 5 months ago

Krystal Biotech granted RMAT designation for KB707 in NSCLC

2026-01-30T12:37:18.000Z - 5 months ago

Krystal Biotech price target raised to $327 from $206 at Goldman Sachs

2026-01-26T11:05:06.000Z - 5 months ago

Krystal Biotech price target raised to $338 from $288 at Clear Street

Jan 15, 2026, 10:31 AM EST - 6 months ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CORT CTRE DCOM DOCN

Jan 12, 2026, 10:30 AM EST - 6 months ago

Krystal Biotech Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 6 months ago

Krystal Biotech Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 1:00 PM EST - 6 months ago

Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 4:30 PM EST - 6 months ago

Krystal Biotech Transcript: Study Update

Jan 8, 2026, 4:30 PM EST - 6 months ago

Krystal Biotech Press release: Study Update

Jan 8, 2026, 4:30 PM EST - 6 months ago

Krystal Biotech Slides: Study Update

Dec 3, 2025, 10:00 AM EST - 7 months ago

Krystal Biotech Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 26, 2025, 8:00 AM EST - 7 months ago

Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

Nov 3, 2025, 8:30 AM EST - 8 months ago

Krystal Biotech Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:30 AM EST - 8 months ago

Krystal Biotech Quarterly report: Q3 2025

Nov 3, 2025, 8:30 AM EST - 8 months ago

Krystal Biotech Earnings release: Q3 2025

Nov 3, 2025, 8:30 AM EST - 8 months ago

Krystal Biotech Slides: Q3 2025

Sep 15, 2025, 8:00 AM EDT - 10 months ago

Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

Sep 4, 2025, 10:20 AM EDT - 10 months ago

Krystal Biotech Transcript: Cantor Global Healthcare Conference 2025

Aug 21, 2025, 12:11 PM EDT - 11 months ago

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

Aug 4, 2025, 8:30 AM EDT - 11 months ago

Krystal Biotech Earnings Call Transcript: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 11 months ago

Krystal Biotech Quarterly report: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 11 months ago

Krystal Biotech Earnings release: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 11 months ago

Krystal Biotech Slides: Q2 2025

Jul 25, 2025, 9:00 AM EDT - 1 year ago

Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

Jul 24, 2025, 4:30 PM EDT - 1 year ago

Krystal Biotech Transcript: Study Result

Jul 24, 2025, 4:30 PM EDT - 1 year ago

Krystal Biotech Press release: Study Result

Jul 24, 2025, 4:30 PM EDT - 1 year ago

Krystal Biotech Slides: Study Result

Jul 24, 2025, 8:00 AM EDT - 1 year ago

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Krystal Biotech Transcript: Study Update

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Krystal Biotech Press release: Study Update

Jul 9, 2025, 8:30 AM EDT - 1 year ago

Krystal Biotech Slides: Study Update

Jul 9, 2025, 7:00 AM EDT - 1 year ago

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

Jun 24, 2025, 7:00 AM EDT - 1 year ago

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa

Jun 10, 2025, 2:00 PM EDT - 1 year ago

Krystal Biotech Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 14, 2025, 2:20 PM EDT - 1 year ago

Krystal Biotech Transcript: BofA Securities 2025 Healthcare Conference

May 7, 2025, 8:00 AM EDT - 1 year ago

Krystal Biotech to Present at BofA Securities 2025 Health Care Conference

May 6, 2025, 8:30 AM EDT - 1 year ago

Krystal Biotech Earnings Call Transcript: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Krystal Biotech Quarterly report: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Krystal Biotech Earnings release: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Krystal Biotech Slides: Q1 2025

Apr 28, 2025, 7:00 AM EDT - 1 year ago

Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Apr 7, 2025, 4:30 PM EDT - 1 year ago

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Krystal Biotech Proxy statement: Proxy Filing

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Krystal Biotech Proxy statement: Proxy Filing

Mar 4, 2025, 1:50 PM EST - 1 year ago

Krystal Biotech Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 28, 2025, 7:40 AM EST - 1 year ago

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Feb 19, 2025, 8:30 AM EST - 1 year ago

Krystal Biotech Earnings Call Transcript: Q4 2024

Feb 19, 2025, 8:30 AM EST - 1 year ago

Krystal Biotech Annual report: Q4 2024

Feb 19, 2025, 8:30 AM EST - 1 year ago

Krystal Biotech Earnings release: Q4 2024

Feb 19, 2025, 8:30 AM EST - 1 year ago

Krystal Biotech Slides: Q4 2024

Feb 19, 2025, 7:00 AM EST - 1 year ago

Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results

Feb 18, 2025, 10:20 AM EST - 1 year ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK CYTK EXE MARA MP

Jan 14, 2025, 8:00 AM EST - 1 year ago

Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

Dec 18, 2024, 8:00 AM EST - 1 year ago

Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer

Dec 12, 2024, 8:30 AM EST - 1 year ago

Krystal Biotech Transcript: Status Update

Dec 12, 2024, 8:30 AM EST - 1 year ago

Krystal Biotech Press release: Status Update

Dec 12, 2024, 8:30 AM EST - 1 year ago

Krystal Biotech Slides: Status Update

Dec 9, 2024, 4:15 PM EST - 1 year ago

Krystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa

Dec 4, 2024, 2:10 PM EST - 1 year ago

Krystal Biotech Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 8:45 AM EST - 1 year ago

Krystal Biotech Transcript: Citi's 2024 Global Healthcare Conference

Nov 27, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech to Present at Upcoming Investor Conferences

Nov 18, 2024, 10:55 AM EST - 1 year ago

Krystal Biotech Transcript: Stifel 2024 Healthcare Conference

Nov 12, 2024, 1:30 PM EST - 1 year ago

Krystal Biotech Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 6, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech to Present at Guggenheim Securities Healthcare Innovation Conference

Nov 4, 2024, 8:30 AM EST - 1 year ago

Krystal Biotech Earnings Call Transcript: Q3 2024

Nov 4, 2024, 8:30 AM EST - 1 year ago

Krystal Biotech Quarterly report: Q3 2024

Nov 4, 2024, 8:30 AM EST - 1 year ago

Krystal Biotech Earnings release: Q3 2024

Nov 4, 2024, 8:30 AM EST - 1 year ago

Krystal Biotech Slides: Q3 2024

Oct 28, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Report Third Quarter 2024 Financial Results on November 4, 2024

Sep 18, 2024, 1:20 PM EDT - 1 year ago

Krystal Biotech Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at 2024 Cantor Global Healthcare Conference

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 4:30 PM EDT - 2 years ago

Krystal Biotech Transcript: Study Result

Aug 28, 2024, 4:30 PM EDT - 2 years ago

Krystal Biotech Press release: Study Result

Aug 28, 2024, 4:30 PM EDT - 2 years ago

Krystal Biotech Slides: Study Result

Aug 5, 2024, 8:30 AM EDT - 2 years ago

Krystal Biotech Earnings Call Transcript: Q2 2024

Aug 5, 2024, 8:30 AM EDT - 2 years ago

Krystal Biotech Quarterly report: Q2 2024

Aug 5, 2024, 8:30 AM EDT - 2 years ago

Krystal Biotech Earnings release: Q2 2024

Aug 5, 2024, 8:30 AM EDT - 2 years ago

Krystal Biotech Slides: Q2 2024

Jul 26, 2024, 8:00 AM EDT - 2 years ago

Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

Jun 11, 2024, 10:40 AM EDT - 2 years ago

Krystal Biotech Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

May 15, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech to Present at the American Thoracic Society 2024 International Conference

May 14, 2024, 5:20 PM EDT - 2 years ago

Krystal Biotech Transcript: BofA Securities 2024 Health Care Conference

May 8, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech to Present at BofA Securities 2024 Health Care Conference

May 6, 2024, 8:30 AM EDT - 2 years ago

Krystal Biotech Earnings Call Transcript: Q1 2024

May 6, 2024, 8:30 AM EDT - 2 years ago

Krystal Biotech Quarterly report: Q1 2024

May 6, 2024, 8:30 AM EDT - 2 years ago

Krystal Biotech Earnings release: Q1 2024

May 6, 2024, 8:30 AM EDT - 2 years ago

Krystal Biotech Slides: Q1 2024

May 6, 2024, 8:00 AM EDT - 2 years ago

Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates

May 2, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting

Apr 26, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024

Apr 22, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Krystal Biotech Proxy statement: Proxy Filing

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Krystal Biotech Proxy statement: Proxy Filing

Apr 4, 2024, 7:00 AM EDT - 2 years ago

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

Feb 28, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 8:30 AM EST - 2 years ago

Krystal Biotech Earnings Call Transcript: Q4 2023

Feb 26, 2024, 8:30 AM EST - 2 years ago

Krystal Biotech Annual report: Q4 2023

Feb 26, 2024, 8:30 AM EST - 2 years ago

Krystal Biotech Earnings release: Q4 2023

Feb 26, 2024, 8:30 AM EST - 2 years ago

Krystal Biotech Slides: Q4 2023

Feb 26, 2024, 8:00 AM EST - 2 years ago

Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Feb 20, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

Feb 13, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung

Feb 8, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa

Feb 7, 2024, 10:00 AM EST - 2 years ago

Krystal Biotech Transcript: Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Feb 1, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference

Jan 4, 2024, 7:00 AM EST - 2 years ago

Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®

Dec 19, 2023, 7:00 AM EST - 2 years ago

Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)

Nov 27, 2023, 7:00 AM EST - 2 years ago

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa

Nov 15, 2023, 11:30 AM EST - 2 years ago

Krystal Biotech Transcript: The Stifel 2023 Annual Healthcare Conference

Nov 9, 2023, 7:00 AM EST - 2 years ago

Krystal Biotech to Present at the Stifel 2023 Healthcare Conference

Nov 6, 2023, 8:30 AM EST - 2 years ago

Krystal Biotech Earnings Call Transcript: Q3 2023

Nov 6, 2023, 8:30 AM EST - 2 years ago

Krystal Biotech Quarterly report: Q3 2023

Nov 6, 2023, 8:30 AM EST - 2 years ago

Krystal Biotech Earnings release: Q3 2023

Nov 6, 2023, 7:00 AM EST - 2 years ago

Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update

zampy Jun. 28 at 2:40 PM

0 · Reply

zampy Jun. 28 at 1:17 PM

0 · Reply

zampy Jun. 27 at 6:16 PM

0 · Reply

zampy Jun. 27 at 3:41 PM

0 · Reply

zampy Jun. 27 at 3:37 PM

0 · Reply

zampy Jun. 27 at 3:23 PM

0 · Reply

Night_Owl_Biotech Jun. 27 at 2:07 PM

3 · Reply

WAJeff Jun. 26 at 11:15 PM

$KRYS $376.28 ath

0 · Reply

WAJeff Jun. 25 at 2:37 PM

$KRYS $357.73 ath

0 · Reply

Cutlass Jun. 22 at 12:50 PM

$KRYS Ahh the good old days in the 30's and 40's - I sold out awhile back - 💥

1 · Reply

Florestan Jun. 21 at 2:39 AM

$KRYS the king of gene therapy. Undisputed.

0 · Reply

WAJeff Jun. 18 at 6:42 PM

$KRYS $356.50 ath

0 · Reply

LewisDaKat Jun. 18 at 10:30 AM

$KRYS These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead https://marketwirenews.com/stock/krys/news/these-3-stocks-have-crushed-the-market-this-year-her-4537015809779451.html?utm_source=stocktwits

0 · Reply

WAJeff Jun. 17 at 3:17 PM

$KRYS $340.79 ath

0 · Reply

SwingTraderPro1 Jun. 11 at 10:26 PM

TODAY’S MARKET READ Seeing some solid pin action from my long book. Still holding index shorts, but longs are clearly outperforming on a relative basis. Long exposure includes: $ASML $VIK $MATX $ROST $KRYS Most of these were positioned ahead of the recent pullback, and they’re now doing the heavy lifting. Net: cautious macro view, but stock-picking alpha is still working. Watching how this divergence plays out into the close.

0 · Reply

WAJeff Jun. 11 at 4:05 PM

$KRYS $325 ath

0 · Reply

ZManicItalian Jun. 9 at 9:29 PM

$KRYS

0 · Reply

Shlobby May. 14 at 2:10 PM

Long $KRYS

1 · Reply

CapitalMonk May. 13 at 4:25 AM

$KRYS Price: $310.31 (-0.82%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±1.00% RSI: 70.1 | Momentum: Strong Momentum Volume: +3.1% vs avg Volatility: 2.58% Support: $251.97 | Resistance: $315.17 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25

0 · Reply

MorganHoratio May. 11 at 9:32 PM

Today, all of these stocks hit all-time highs at some point. Arrow Electronics $ARW Powell Industries $POWL Synnex $SNX Krystal Biotech $KRYS Enersys $ENS Today’s ATH list is a perfect showcase of a "Multi-Sector Breakout" across AI infra, Life Sciences, and Supply Chain! 🚀 As of May 11, 2026, $POWL hitting $328 reaffirms its dominance in power distribution. $ARW crossing $202 and $ENS breaking $236 highlight the massive recovery in AI hardware distribution and energy storage. Notably, $KRYS tapping $315 marks a pivotal re-rating for the biotech sector. The takeaway: 2026’s wealth effect is flowing beyond GPUs into "Power, Distribution, and Deep-Tech Bio." Which of these "non-GPU" leaders do you think has the most room to run? Let’s discuss your 2026 strategy below!

1 · Reply

ZManicItalian May. 11 at 2:02 PM

$KRYS 🍻🐂

0 · Reply

Doozio May. 9 at 12:57 AM

$KRYS ONTO 🐒🍌🧠⏰♾️

0 · Reply

Market Cap	11.06B
Revenue (ttm)	389.13M
Net Income (ttm)	204.83M
EPS (ttm)	N/A
PE Ratio	49.68
Forward PE	48.51
Profit Margin	52.64%
Debt to Equity Ratio	0.00

Volume	235,200
Avg Vol	329,046
Day's Range	N/A - N/A
Shares Out	29.48M
Stochastic %K	83%
Beta	0.50
Analysts	Strong Sell
Price Target	$350.00